Broncus Biomedical

Broncus Medical, a pioneer in the field of interventional pulmonology, provides innovative solutions for lung diseases in China and globally. Broncus Medical has assembled a management team with extensive experience in product development, clinical research, and commercialization, and has grown into a company with dual centers in China and the United States, holding a diversified intellectual property portfolio. As of June 30, 2022, Broncus Medical has obtained 676 patents and patent applications. Through close connections with global KOLs in the respiratory intervention field, the company has established comprehensive linkages from innovative concepts to project development and execution, building a robust pipeline of 17 interventional diagnostic and therapeutic products, with multiple products already commercialized in major global markets including the United States, Europe, and Australia. Our vision: to become the global leader in transforming lung disease treatment. Our mission: to establish interventional diagnostic and therapeutic solutions as the gold standard for lung disease treatment. Declaring war on lung cancer and COPD, we are pioneers in interventional pulmonology, providing innovative lung disease solutions in China and globally. In the large, undeveloped, and rapidly growing interventional pulmonology market, supported by China's first and only whole-lung navigation technology with real-time imaging, we have established a trinity of comprehensive interventional respiratory disease treatment platforms, addressing the pain points of current diagnostic and therapeutic models and the far-from-met clinical needs of lung diseases, guiding the paradigm shift in diagnosis and treatment, and advancing the field into the era of precision diagnosis and treatment.